Negroni R, Helou S H, López Daneri G, Robles A M, Arechavala A I, Bianchi M H
Unidad Micología, Hospital de Infecciosas Francisco Javier Muñiz, Uspallata 2272, (1282), Ciudad Autónoma de Buenos Aires, Argentina.
Rev Argent Microbiol. 2004 Jul-Sep;36(3):113-7.
The clinical and laboratory data of 22 patients with AIDS related cryptococcosis who were able to interrupt antifungal secondary prophylaxis after HAART administration, are presented. They were 14 males and 8 females, between 15 and 50 years old (X: 34 years old). All patients presented fever and severe deterioration of their general health status, and 19 exhibited a meningeal syndrome. At the start of antifungal treatment, 59% of the cases presented < 50 CD4+ cells/microl, the median viral burden was 134,804 RNA copies/ml and the median titer of serum cryptococcal antigen was 1/3,000. Amphotericin B by intravenous route, (0.7 mg/kg/day) or fluconazole (600 to 800 mg/day) were given as a treatment of the initial episode, up to CSF cultures negativization. Oral fluconazole (200 mg/day) or intravenous amphotericin B, 50 mg twice a week, were given as a secondary prophylaxis. The secondary prophylaxis was interrupted when the patients had received HAART for an average lapse of 19 months (6 to 36 months) and the median CD4+ cell count was 249/microl. The follow up after secondary prophylaxis discontinuation lasted for a median lapse of 22 months. These data seem to show that secondary prophylaxis is not necessary when the patient are clinically asymptomatic and the CD4+ cell counts are above 150/microl.
本文呈现了22例艾滋病相关隐球菌病患者的临床和实验室数据,这些患者在接受高效抗逆转录病毒治疗(HAART)后能够中断抗真菌二线预防治疗。他们中男性14例,女性8例,年龄在15至50岁之间(平均年龄:34岁)。所有患者均出现发热及全身健康状况严重恶化,19例表现出脑膜综合征。在抗真菌治疗开始时,59%的病例CD4+细胞计数<50个/微升,病毒载量中位数为134,804 RNA拷贝/毫升,血清隐球菌抗原滴度中位数为1/3,000。初始治疗阶段采用静脉注射两性霉素B(0.7毫克/千克/天)或氟康唑(600至800毫克/天),直至脑脊液培养转阴。二线预防采用口服氟康唑(200毫克/天)或静脉注射两性霉素B(50毫克,每周两次)。当患者接受HAART平均19个月(6至36个月)且CD4+细胞计数中位数为249/微升时,中断二线预防治疗。二线预防治疗中断后的随访时间中位数为22个月。这些数据似乎表明,当患者临床无症状且CD4+细胞计数高于150/微升时,无需进行二线预防治疗。